TransGenic Group

TransGenic Group Graham Number

The Graham Number of TransGenic Group (2342.T) as of Nov 5, 2026 is 43.74 JPY. In the previous year, Graham Number was 981.01 JPY — a change of -95.54% (lower).

Graham Number

43.74JPY

YoY

-95.54%

Last updated:

Graham Number of TransGenic Group is 2024 43.74 JPY. Graham Number of TransGenic Group was 2023 981.01 JPY. It decreases by -95.54% lower compared to the previous year.

The TransGenic Group Graham Number history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Graham Number
Date
Graham Number
Jan 1, 2015
62.72 JPY
Jan 1, 2016
64.26 JPY
Jan 1, 2017
150.99 JPY
Jan 1, 2018
83.73 JPY
Jan 1, 2019
274.42 JPY
Jan 1, 2021
459.75 JPY
Jan 1, 2022
981.01 JPY
Jan 1, 2024
43.74 JPY
The TransGenic Group Graham Number history
YEARGraham NumberYoY
43.74JPY-95.54%
981.01JPY+113.38%
459.75JPY+67.53%
274.42JPY+227.73%
83.73JPY-44.54%
150.99JPY+134.98%
64.26JPY+2.45%
62.72JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TransGenic Group stock

Graham Number of TransGenic Group is 43.74 JPY in 2024.

On Eulerpool you can find the complete historical development of Graham Number TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

The Graham Number estimates the maximum fair price for a stock based on EPS and book value per share, following Benjamin Graham's value investing principles.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — TransGenic Group

All Key Metrics — TransGenic Group